ArticleScientific reports2026
Analyzing fourteen deleterious nsSNPs of CFTR as promising genetic markers for cancer prognosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel protein involved in trans-epithelial transport of salt and the regulation of intracellular ion concentrations. The present study aims to investigate the relationship between CFTR non-synonymous SNPs (nsSNPs) and cancer. The study also seeks to elucidate the structural and functional consequences of the deleterious CFTR variants on the protein. The CFTR nsSNPs were retrieved from the Ensembl genome browser, and the deleterious nsSNPs were filtered out using PredictSNP2, CADD, FunSeq2 and GWAVA. The most pathogenic nsSNPs were shortlisted for further analysis. By employing I-TASSER, ProjectHOPE, I-Mutant, MUpro, DynaMut and MutPred, the influence of SNPs on the function and structure of the protein was assessed. Secondary and tertiary structures were predicted through PSIPRED and AlphaFold. Normal Mode Analysis (NMA) were performed through IMOD software, while the RMSD values of the mutated structures were determined through myPresto. Genotyping analyses were conducted through Tetra-primer ARMS-PCR (Amplification Refractory Mutation System). Fourteen nsSNPs of CFTR were identified as deleterious, significantly decreasing protein stability and potentially contributing to carcinogenesis. The pathogenic variants were mapped onto the ATP-binding cassette domain, indicating a strong association with altered protein function. Structural analyses indicated that the nsSNPs could induce changes in residue interactions with neighboring residues, thereby affecting the protein stability and molecular interactions. Normal Mode Analysis confirmed that these variants could perturb the CFTR's conformational integrity. The genotyping analysis indicated that the heterozygous (AT) genotype of rs556880586 was highly prevalent in patients (70%) in comparison to controls (19%). Testing through Hardy-Weinberg Equilibrium (HWE) showed significant deviation in both patient and control groups for the nsSNPs, rs556880586 and rs949472192. Outcomes of the current study identified two deleterious nsSNPs in the CFTR gene that can possibly contribute to cancer progression. Moreover, these variants could act as preliminary biomarker candidates for clinical validation. The obtained knowledge gained from the current research could eventually assist in disease diagnosis and therapy design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.